Prospective multicenter study with a 1-year analysis of a new vascular graft used for early cannulation in patients undergoing hemodialysis

Glickman, Marc H.; Burgess, Jason; Cull, David L.; Roy‐Chaudhury, Prabir; Schanzer, Harry

doi:10.1016/j.jvs.2015.03.020

Cited by 58 publications

(50 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Emerging alternatives to conventional polytetrafluoroethylene grafts, such as early-cannulation polytetrafluoroethylene conduits, have the potential advantage of reducing catheter dependence, but this is offset by the use of synthetic conduit for access creation (14,15). Therefore, improvements in catheter technology that can reduce the rate of catheter dysfunction will be critical toward improving clinical outcomes in dialysis recipients and reducing health care costs for patients with end-stage renal disease.…”

Section: Discussionmentioning

confidence: 99%

Initial Clinical Experience: Symmetric-Tip Dialysis Catheter with Helical Flow Characteristics Improves Patient Outcomes

Clark

Redmond

Mantell

et al. 2015

Journal of Vascular and Interventional Radiology

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Initial Clinical Experience: Symmetric-Tip Dialysis Catheter with Helical Flow Characteristics Improves Patient Outcomes

Clark

Redmond

Mantell

et al. 2015

Journal of Vascular and Interventional Radiology

View full text Add to dashboard Cite

“…In a study of 275 patients who were using Acuseal graft for HD, Acuseal provided early cannulation at 72 hours without any complications. 10 No excessive bleeding or hematoma was reported in these patients. The primary patency rates at 12 months were also similar to standard grafts.…”

Section: Acuseal Graftmentioning

confidence: 75%

“…Acuseal was approved by Food and Drug Administration in 2013 for early cannulation. In a study of 275 patients who were using Acuseal graft for HD, Acuseal provided early cannulation at 72 hours without any complications . No excessive bleeding or hematoma was reported in these patients.…”

Section: Discussionmentioning

confidence: 99%

Successful use of arterio‐venous graft for hemodialysis in patient with hemophilia

Amberker

Rampure

2018

Hemodialysis International

View full text Add to dashboard Cite

Hemodialysis (HD) is not the preferred approach for dialysis in patients with hemophilia. HD in such patients can possess a high risk of bleeding from arterio‐venous cannulation and hence peritoneal dialysis is the first choice in patients with hemophilia. The bleeding risk can be overcome by the prophylactic administration of factor VIII, which is a very costly solution. Here, we present a case of hemophilia with successful HD using an arterio‐venous graft averting the need for factor VIII. We review the literature on epidemiology and risk factors for chronic kidney disease in patients with hemophilia. We also discuss the dialysis and arterio‐venous graft options. In patients with hemophilia who are not candidates for peritoneal dialysis, tri‐layered arterio‐venous grafts offer distinct advantages.

show abstract

“…Some AVG may have benefited from the placement of an "early access" graft, which could justify a time to first use of < 15 days. However, "early access" grafts still comprise a small percentage of all prosthetic grafts placed 2012-2014, likely due to marginal performance and slow patient and provider adoption curves [22].…”

Section: Doi: 101159/000495355mentioning

confidence: 99%

Clinical Outcomes of Arteriovenous Access in Incident Hemodialysis Patients with Medicare Coverage, 2012–2014

et al. 2019

Self Cite

View full text Add to dashboard Cite

Background: Chronic hemodialysis requires a mode of vascular access through an arteriovenous fistula (AVF), a prosthetic arteriovenous graft (AVG), or a central venous catheter (CVC). AVF is recommended over AVG or CVC due to increased patency and decreased intervention rates for those that mature. AVG are preferred over CVC due to decreased infection and mortality risk. The aims of this study were to evaluate the lifespan of AVF and AVG in maturation, sustained access use, and abandonment. Methods: The United States Renal Data System (USRDS), Medicare claims, and CROWNWeb were used to identify access placements. Patients with a first end-stage renal disease (ESRD) service from January 1, 2012 to June 30, 2014 with continuous coverage with Medicare as primary payer and ≥1 AVF or AVG placed after ESRD onset were included. Maturation was defined as the first use of the access for hemodialysis recorded in CROWNWeb. Sustained access use was defined as 3 consecutive months of use without catheter placement or replacement. Accesses that were never used at any time post-placement were considered abandoned. Results: The cohort included 38,035 AVF placements and 12,789 AVG placements. Sixty-nine percent of AVF and 72% of AVG matured. Fifty-two percent of AVF and 51% of AVG achieved sustained access use. One quarter of AVF and 14% of AVG were abandoned without use as recorded in CROWNWeb. Conclusion: Although considered the gold standard for vascular access, only half of AVF and AVG placements achieved sustained access use. The USRDS database has inherent limitations but provides useful clinical insight into maturation, sustained use, and abandonment.

show abstract

Prospective multicenter study with a 1-year analysis of a new vascular graft used for early cannulation in patients undergoing hemodialysis

Cited by 58 publications

References 31 publications

Initial Clinical Experience: Symmetric-Tip Dialysis Catheter with Helical Flow Characteristics Improves Patient Outcomes

Initial Clinical Experience: Symmetric-Tip Dialysis Catheter with Helical Flow Characteristics Improves Patient Outcomes

Successful use of arterio‐venous graft for hemodialysis in patient with hemophilia

Clinical Outcomes of Arteriovenous Access in Incident Hemodialysis Patients with Medicare Coverage, 2012–2014

Contact Info

Product

Resources

About